Location & dates EMBL Heidelberg, Germany 30 Apr - 3 May 2014
Deadlines Registration closed Abstract submission closed
EES_logo

EMBL Courses and Conferences during the Coronavirus pandemic

With the onsite programme paused, many of our events are now being offered in virtual formats.


Registration is open as usual for many events, with back-up plans in place to move further courses and conferences online as necessary. Registration fees for any events affected by the COVID-19 disruption are fully refundable.


More information for participants of events at EMBL Heidelberg can be found here.

Latest News



Why attend

Summary

Over recent decades, the incidence of metabolic diseases such as obesity and diabetes has risen to epidemic proportions. Projections into the future suggest increasingly unmet patient needs and an unsustainable challenge for health care systems. Simultaneously, the drug discovery process is facing its own challenges. The number of pharmaceutical companies who are able to conduct expensive late stage clinical trials is declining. Funding for academic laboratories and biotechnology operations is limited. Novel strategies and new insights are needed to treat these diseases.

The 2014 EMBO | EMBL Symposium will focus on "translation" from bench to bedside and from model organism to the clinic.

Aims of event

This EMBO | EMBL Symposium aims to bring together established experts, physician scientists and basic researchers to discuss the multi-layered and complex processes leading up to novel therapeutic strategies for diabetes, obesity and related health issues, such as cancer and cardiovascular disease, including:

  • Mechanistic translational research addressing controversies of clinical relevance for diabetes and obesity
  • Systems biology approaches dissecting multi-organ communication in the pathophysiology of metabolic disease
  • Unraveling the emerging molecular interplays between immune processes and metabolic pathways
  • Exploring novel insight into mechanisms of bariatric surgery and combination therapies for the development of future pharmacologics